Zacks: Brokerages Expect Savara Inc (NASDAQ:SVRA) to Announce -$0.08 Earnings Per Share

Analysts expect Savara Inc (NASDAQ:SVRAGet Rating) to announce earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Savara’s earnings, with estimates ranging from ($0.08) to ($0.07). Savara reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Savara will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.29). For the next financial year, analysts expect that the firm will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.32) to ($0.31). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Savara.

Savara (NASDAQ:SVRAGet Rating) last issued its earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07).

Separately, Zacks Investment Research cut shares of Savara from a “hold” rating to a “sell” rating in a report on Tuesday, April 5th.

Shares of Savara stock remained flat at $$1.29 during trading hours on Tuesday. 1,724 shares of the stock traded hands, compared to its average volume of 127,775. The company’s fifty day moving average price is $1.20 and its 200-day moving average price is $1.21. Savara has a fifty-two week low of $1.02 and a fifty-two week high of $2.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.26 and a current ratio of 11.26. The firm has a market cap of $147.11 million, a P/E ratio of -3.79 and a beta of 1.04.

A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its position in Savara by 47.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 106,410 shares of the company’s stock worth $132,000 after buying an additional 34,221 shares during the last quarter. Millennium Management LLC raised its position in Savara by 12.6% during the 4th quarter. Millennium Management LLC now owns 388,387 shares of the company’s stock worth $482,000 after buying an additional 43,427 shares during the last quarter. Sio Capital Management LLC purchased a new position in shares of Savara in the 4th quarter valued at about $807,000. Renaissance Technologies LLC increased its holdings in shares of Savara by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 344,492 shares of the company’s stock valued at $427,000 after purchasing an additional 33,292 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Savara by 191.7% in the 4th quarter. JPMorgan Chase & Co. now owns 160,155 shares of the company’s stock valued at $198,000 after purchasing an additional 105,256 shares in the last quarter. Institutional investors own 70.52% of the company’s stock.

About Savara (Get Rating)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.